MiMedx Group, Inc. MDXG

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product Order Further Holds That Minimal-Manipulation Analysis Must Consider Tissue Characteristics Relevant to Reconstruction, Repair or Replacement in the Recipient MARIETTA, Ga., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. District Court for the Northern District of Georgia issued a favorable rul

MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Cantor Global Healthcare Conference | New York, NYWednesday, September 9, 20261:1 sessions Lake Street BIG10 Best Ideas Growth Conference | New York, NYThursday, September 10, 20261:1 sessions Investors interested in meeting with senior management at these events may contact th

Moby summary of MiMedx Group, Inc.'s Q2 2026 earnings call

MiMedx reports strong surgical momentum and a transformational acquisition, while navigating a challenging wound care market with early signs of stabilization.

Reports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2026. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "During the second quarter,

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm EDT MARIETTA, Ga.

MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, July 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webc

MiMedx Group is back in focus as analysts revisit their price targets, with several firms trimming expectations by roughly US$1 to US$5 while the modeled fair value sits at US$6.50. Those moves line up with research that balances optimism about MiMedx Group’s business against concerns around execution and how the stock is currently priced. Read on to see what these shifts could mean for you and how to track the evolving analyst narrative from here. Stay updated as the Fair Value for MiMedx...

Recent Street research on MiMedx Group has centered on trimming price targets by US$1 to US$5 at a time, as analysts recheck their assumptions. Those smaller step downs, whether bullish or bearish, line up with commentary that suggests many analysts are fine tuning their views on profitability and execution rather than completely rethinking the stock. As you read on, you will see how to track these price target moves and what they might signal for the evolving narrative around MiMedx...

MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a

MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. Our...

MiMedx Group is back in focus after analysts trimmed fair value estimates, with one key model now pointing to a reduced price target range that includes a shift from US$8.20 to US$6.50 per share. That change sits alongside broader research that highlights both pressure from reimbursement questions and specific factors that some analysts still see as supportive for the chronic wound care business over time. Read on to see what is driving the evolving narrative and how you can track it as new...

It's shaping up to be a tough period for MiMedx Group, Inc. ( NASDAQ:MDXG ), which a week ago released some...

MiMedx Group Inc. (NASDAQ:MDXG) is one of the best biotech penny stocks to buy in 2026. On March 23, MiMedx officially announced the commercial launch of CHORIOFIX, the latest addition to its portfolio of advanced placental allografts. This organically developed product is a lyophilized human placental allograft designed to serve as a protective barrier for […]

MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual